Long-term effects of a short course of neoadjuvant luteinizing hormone-releasing hormone analogue and radical radiotherapy on the hormonal profile in patients with localized prostate cancer
Open Access
- 25 May 2007
- journal article
- Published by Wiley in BJU International
- Vol. 99 (6) , 1380-1382
- https://doi.org/10.1111/j.1464-410x.2007.06843.x
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Recovery of serum testosterone after neoadjuvant androgen deprivation therapy and radical radiotherapy in localized prostate cancerBJU International, 2006
- 6-Month Androgen Suppression Plus Radiation Therapy vs Radiation Therapy Alone for Patients With Clinically Localized Prostate CancerJAMA, 2004
- Longitudinal Effects of Aging on Serum Total and Free Testosterone Levels in Healthy MenJournal of Clinical Endocrinology & Metabolism, 2001
- Longitudinal Relation between Endogenous Testosterone and Cardiovascular Disease Risk Factors in Middle-aged Men: A 13-Year Follow-up of Former Multiple Risk Factor Intervention Trial ParticipantsAmerican Journal of Epidemiology, 1997
- Longitudinal changes in testosterone, luteinizing hormone, and follicle-stimulating hormone in healthy older menMetabolism, 1997
- Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localized prostate cancerInternational Journal of Radiation Oncology*Biology*Physics, 1997
- Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the radiation therapy oncology groupUrology, 1995
- The Effects of External Beam Radiotherapy on Endocrine Function in Patients with Carcinoma of the ProstateJournal of Urology, 1986
- Treatment of Prostatic Cancer with a Gonadotropin-Releasing Hormone Agonist Analog: Acute and Long Term Effects on Endocrine Functions of Testis Tissue*Journal of Clinical Endocrinology & Metabolism, 1985
- Effects of External Radiation Therapy for Cancer of the Prostate on the Serum Concentrations Of Testosterone, Follicle-Stimulating Hormone, Luteinizing Hormone and ProlactinJournal of Urology, 1983